These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1407 related articles for article (PubMed ID: 32063058)

  • 21. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?
    Sabrià E; Lequerica-Fernández P; Ganuza PL; Ángeles EE; Escudero AI; Martínez-Morillo E; Alvárez FV
    Clin Chem Lab Med; 2018 Jan; 56(2):303-311. PubMed ID: 28841572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of sFlt-1/PlGF ratio in preeclampsia : a monocentric retrospective analysis].
    Verbeurgt L; Chantraine F; De Marchin J; Minon JM; Nisolle M
    Rev Med Liege; 2017 Sep; 72(9):393-398. PubMed ID: 28892314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.
    Lecarpentier É; Vieillefosse S; Haddad B; Fournier T; Leguy MC; Guibourdenche J; Tsatsaris V
    Ann Biol Clin (Paris); 2016 Jun; 74(3):259-67. PubMed ID: 27237799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing.
    Espinoza J; Calsavara VF; Kilpatrick S; Rana S; Costantine MM; Boggess K; Wylie BJ; Moore Simas TA; Louis JM; Gaw SL; Murtha A; Wiegand S; Gollin Y; Singh D; Silver RM; Durie DE; Panda B; Norwitz ER; Burd I; Plunkett B; Scott RK; Lemoine E; Thadhani R; Karumanchi SA
    Am J Obstet Gynecol; 2024 Sep; 231(3):363.e1-363.e11. PubMed ID: 38825028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome.
    Stepan H; Hund M; Gencay M; Denk B; Dinkel C; Kaminski WE; Wieloch P; Semus B; Meloth T; Dröge LA; Verlohren S
    Hypertens Pregnancy; 2016 Aug; 35(3):295-305. PubMed ID: 27028698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia.
    Stolz M; Zeisler H; Heinzl F; Binder J; Farr A
    Pregnancy Hypertens; 2018 Jan; 11():54-60. PubMed ID: 29523274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiogenic factors during pregnancy in Asian women with elevated blood pressure in early pregnancy and the risk of preeclampsia: a longitudinal cohort study.
    Zhu J; Zhang J; Ng MJ; Chern B; Yeo GS; Tan KH
    BMJ Open; 2019 Dec; 9(11):e032237. PubMed ID: 31791965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women.
    Sovio U; Gaccioli F; Cook E; Hund M; Charnock-Jones DS; Smith GC
    Hypertension; 2017 Apr; 69(4):731-738. PubMed ID: 28167687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Angiogenic Markers in Pregnant Women With Chronic Hypertension.
    Binder J; Palmrich P; Kalafat E; Pateisky P; Öztürk E; Mittelberger J; Khalil A
    J Am Heart Assoc; 2021 Sep; 10(17):e020631. PubMed ID: 34459247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of Soluble FMS-like Tyrosine Kinase 1/Placental Growth Factor Ratio in the Clinical Management of Pre-eclampsia.
    Govender N; Moodley J; Naicker T
    Afr J Reprod Health; 2018 Dec; 22(4):135-143. PubMed ID: 30632730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol.
    Hund M; Allegranza D; Schoedl M; Dilba P; Verhagen-Kamerbeek W; Stepan H
    BMC Pregnancy Childbirth; 2014 Sep; 14():324. PubMed ID: 25230734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction.
    Stepan H; Galindo A; Hund M; Schlembach D; Sillman J; Surbek D; Vatish M
    Ultrasound Obstet Gynecol; 2023 Feb; 61(2):168-180. PubMed ID: 35816445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The sFlt-1/PlGF ratio values within the <38, 38-85 and >85 brackets as compared to perinatal outcomes.
    Bednarek-Jędrzejek M; Kwiatkowski S; Ksel-Hryciów J; Tousty P; Nurek K; Kwiatkowska E; Cymbaluk-Płoska A; Torbé A
    J Perinat Med; 2019 Sep; 47(7):732-740. PubMed ID: 31339858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia.
    Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO
    BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of angiogenic markers in pregnancy with fetal growth restriction.
    Palmrich P; Kalafat E; Pateisky P; Schirwani-Hartl N; Haberl C; Herrmann C; Khalil A; Binder J
    Ultrasound Obstet Gynecol; 2024 May; 63(5):619-626. PubMed ID: 37774098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
    Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
    J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.